Safinamide Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg ,100 mg
Reference Brands: Xadago (USA/EU)
Category:
Neurology
Safinamide is available in Tablets
and strengths such as 50 mg ,100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Safinamide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Safinamide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Safinamide is a medication used in the management of idiopathic Parkinson’s disease in adults who experience motor fluctuations, commonly known as “off” episodes. It is marketed under the brand name Xadago and is prescribed as an add-on therapy for patients receiving a stable dose of levodopa, either alone or in combination with other Parkinson’s disease treatments. Safinamide is particularly beneficial for patients whose symptoms re-emerge when the effects of levodopa wear off.
Safinamide has a unique and multi-modal mechanism of action. It acts as a selective and reversible inhibitor of monoamine oxidase B (MAO-B), an enzyme responsible for the breakdown of dopamine in the brain. By inhibiting MAO-B, safinamide helps increase and prolong dopamine activity, improving motor control. In addition, safinamide modulates abnormal glutamate release, which contributes to both motor and non-motor symptom control.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing